References
- McNeil MM, DeStefano F. Vaccine-associated hypersensitivity. J Allergy Clin Immunol. 2018;141(2):463–472. doi:10.1016/j.jaci.2017.12.971
- World Health Organization. Interim recommendations for use of the inactivated COVID-19 vaccine, CoronaVac, developed by Sinovac; 24 May 2021. Available from: https://apps.who.int/iris/bitstream/handle/10665/341454/WHO-2019-nCoV-vaccines-SAGE-recommendation-Sinovac-CoronaVac-2021.1-eng.pdf. Accessed July,29 2021.
- Thai Food and Drug Administration (Thai FDA). Available from: https://www.fda.moph.go.th/sites/drug/Shared%20Documents/Vaccine/U1DR1C1072640000311C-SPC-EN.pdf. Accessed July 29, 2021.
- Data from the Ministry of Public Health. Thailand. Available from: https://ddc.moph.go.th/uploads/ckeditor2//files/Daily%20report%202021-05-30.pdf. Accessed July. 29, 2021.
- Ruggeberg JU, Gold MS, Bayas JM, et al. Anaphylaxis: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. Vaccine. 2007;25(31):5675–5684. doi:10.1016/j.vaccine.2007.02.064
- Valent P, Bonadonna P, Hartmann K, et al. Why the 20% + 2 tryptase formula is a diagnostic gold standard for severe systemic mast cell activation and mast cell activation syndrome. Int Arch Allergy Immunol. 2019;180(1):44–51. doi:10.1159/000501079
- Xia S, Zhang Y, Wang Y, et al. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, Phase 1/2 trial. Lancet Infect Dis. 2021;21(1):39–51. doi:10.1016/S1473-3099(20)30831-8
- Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, Phase 3 trial in Turkey. Lancet. 2021;398(10296):213–222. doi:10.1016/S0140-6736(21)01429-X
- Jara A, Undurraga EA, Gonzalez C, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385(10):875–884. doi:10.1056/NEJMoa2107715
- Muraro A, Worm M, Alviani C, et al. EAACI guideline: anaphylaxis (2021 update). Allergy. 2021. doi:10.1111/all.15032
- Kounis NG, Koniari I, de Gregorio C, et al. Allergic reactions to current available COVID-19 vaccinations: pathophysiology, causality, and therapeutic considerations. Vaccines. 2021;9(3):221.
- Risma KA, Edwards KM, Hummell DS, et al. Potential mechanisms of anaphylaxis to COVID-19 mRNA vaccines. J Allergy Clin Immunol. 2021;147(6):2075–82 e2. doi:10.1016/j.jaci.2021.04.002
- Guven E, Duus K, Laursen I, Hojrup P, Houen G. Aluminum hydroxide adjuvant differentially activates the three complement pathways with major involvement of the alternative pathway. PLoS One. 2013;8(9):e74445. doi:10.1371/journal.pone.0074445
- Stone CA Jr., Rukasin CRF, Beachkofsky TM, Phillips EJ. Immune-mediated adverse reactions to vaccines. Br J Clin Pharmacol. 2019;85(12):2694–2706. doi:10.1111/bcp.14112
- Kutlu A, Ucar R, Aydin E, Arslan S, Caliskaner AZ. Could aluminum be a new hidden allergen in type 1 hypersensitivity reactions when used as a drug additive? Postepy Dermatol Alergol. 2016;33(3):243–245. doi:10.5114/ada.2016.60620
- Cogne M, Ballet JJ, Schmitt C, Bizzini B. Total and IgE antibody levels following booster immunization with aluminum absorbed and nonabsorbed tetanus toxoid in humans. Ann Allergy. 1985;54(2):148–151.
- Krantz MS, Kwah JH, Stone CA Jr., et al. Safety evaluation of the second dose of messenger RNA COVID-19 vaccines in patients with immediate reactions to the first dose. JAMA Intern Med. 2021. doi:10.1001/jamainternmed.2021.3779
- Krantz MS, Bruusgaard-Mouritsen MA, Koo G, Phillips EJ, Stone CA Jr., Garvey LH. Anaphylaxis to the first dose of mRNA SARS-CoV-2 vaccines: don’t give up on the second dose! Allergy. 2021;76(9):2916–2920. doi:10.1111/all.14958
- Mustafa SS, Ramsey A, Staicu ML. Administration of a second dose of the moderna COVID-19 vaccine after an immediate hypersensitivity reaction with the first dose: two case reports. Ann Intern Med. 2021;174(8):1177–1178. doi:10.7326/L21-0104
- Wolfson AR, Robinson LB, Li L, et al. First-dose mRNA COVID-19 vaccine allergic reactions: limited role for excipient skin testing. J Allergy Clin Immunol Pract. 2021;9(9):3308–3320.e3. doi:10.1016/j.jaip.2021.06.010
- Kessel A, Bamberger E, Nachshon L, Rosman Y, Confino-Cohen R, Elizur A. Safe administration of the Pfizer-BioNtTech COVID-19 vaccine following an immediate reaction to the first dose. Allergy. 2021. doi:10.1111/all.15038
- World Health Organization. Background document on the inactivated vaccine Sinovac-CoronaVac against COVID-19. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-Sinovac-CoronaVac-background-2021.1. Accessed July 29, 2021.
- Dreskin SC, Halsey NA, Kelso JM, et al. International Consensus (ICON): allergic reactions to vaccines. World Allergy Organ J. 2016;9(1):32. doi:10.1186/s40413-016-0120-5
- Wood RA, Setse R, Halsey N; Clinical Immunization Safety Assessment Network Hypersensitivity Working G. Irritant skin test reactions to common vaccines. J Allergy Clin Immunol. 2007;120(2):478–481. doi:10.1016/j.jaci.2007.04.035